Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release 4-aminopyridine (Fampyra) in the treatment of cerebellar ataxia
DRKS00005271Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalfampridine in Genetic Ataxias, cerebellar ataxia (CA), sponsored by LMU Klinikum. Started Oct 2013; status: completed.
02
Drugs
dalfampridine
03
Conditions
Genetic Ataxiascerebellar ataxia (CA)
Beyond the preview
Go deeper on DRKS00005271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005271.